




## N<sup>6</sup>-(4-Amino)butyl-ATP

N<sup>6</sup>-(4-Amino)butyl-adenosine-5'-triphosphate, Sodium salt

Cat. No.	Amount
NU-804S	50 µl (10 mM)
NU-804L	5 x 50 µl (10 mM)



Structural formula of N<sup>6</sup>-(4-Amino)butyl-ATP

### For research use only!

**Shipping:** shipped on gel packs

**Storage Conditions:** store at -20 °C

Short term exposure (up to 1 week cumulative) to ambient temperature possible.

**Shelf Life:** 12 months after date of delivery

**Molecular Formula:** C<sub>14</sub>H<sub>25</sub>N<sub>6</sub>O<sub>13</sub>P<sub>3</sub> (free acid)

**Molecular Weight:** 578.30 g/mol (free acid)

**Exact Mass:** 578.07 g/mol (free acid)

**CAS#:** 280577-98-2

**Purity:** ≥ 95 % (HPLC)

**Form:** solution in water

**Color:** colorless to slightly yellow

**Concentration:** 10 mM - 11 mM

**pH:** 7.5 ± 0.5

**Spectroscopic Properties:** λ<sub>max</sub> 266 nm, ε 16.2 L mmol<sup>-1</sup> cm<sup>-1</sup> (Tris-HCl pH 7.5)

### Applications:

Agonistic ligand, mainly for nucleoside receptor A<sub>1</sub>. Nucleoside-triphosphates can be converted by different membrane-bound phosphatases into nucleosides acting as nucleoside receptor ligands. In some cases nucleoside phosphates act also directly on nucleoside receptors.

### Selected References:

Sirci *et al.* (2012) Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> receptor antagonists. *J. Comput. Aided Mol. Des.* **26**:1247.

Volonte *et al.* (2009) Membrane components and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. *FEBS J.* **276**:318.

Yegutkin (2008) Nucleotide and nucleoside converting enzymes: Important modulators of purinergic signalling cascade. *Biochim. Biophys. Acta* **1783**:673.

Joshi *et al.* (2005) Purine derivatives as ligands for A<sub>3</sub> adenosine receptors. *Current Topics in Medicinal Chemistry* **5**:1275.

Hess (2001) Recent advantages in adenosine receptor antagonist research. *Expert Opin. Ther. Patents* **11** (10):1533.

Jacobson (2001) Probing adenosine and P<sub>2</sub> receptors: design of novel purines and nonpurines as selective ligands. *Drug Development Res.* **52**:178.

Jacobson *et al.* (2001) Ribose modified nucleosides and nucleotides as ligands for purine receptors. *Nucleosides, Nucleotides & Nucleic Acids* **20** (4):333.

Van Galen *et al.* (1994) A binding site model and structure-activity relationships for rat A<sub>3</sub> adenosine receptor. *Molecular Pharmacology* **45**:1101.